Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | T2333Nfs*40 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM T2333Nfs*40 indicates a shift in the reading frame starting at amino acid 2333 and terminating 40 residues downstream causing a premature truncation of the 3056 amino acid Atm protein (UniProt.org). T2333Nfs*40 has not been characterized, however, due to the effects of other truncation mutations downstream of T2333 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM T2333fs ATM T2333Nfs*40 |
Transcript | NM_000051.4 |
gDNA | chr11:g.108327666dupA |
cDNA | c.6997dupA |
Protein | p.T2333Nfs*40 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006718843.5 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_011542843 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_006718843 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_017017789 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
NM_000051 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_005271561 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_011542840 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_005271562 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
XM_017017790 | chr11:g.108327666dupA | c.6997dupA | p.T2333Nfs*40 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM T2333Nfs*40 | pancreatic ductal adenocarcinoma | no benefit | Fluorouracil + Oxaliplatin + Veliparib | Case Reports/Case Series | Actionable | In a Phase I/II trial, Veliparib (ABT-888) in combination with Adrucil (fluorouracil) and Eloxatin (oxaliplatin) did not result in a clinical response in a patient with metastatic pancreatic ductal adenocarcinoma harboring ATM T2333Nfs*40 (reported as c.6997dupA) (PMID: 32669374; NCT01489865). | 32669374 |